Oral Long-Acting PTH Tablet
Hypoparathyroidism
PreclinicalActive (Partnership with Entera Bio)
Key Facts
Indication
Hypoparathyroidism
Phase
Preclinical
Status
Active (Partnership with Entera Bio)
Company
About Opko Health
OPKO Health is a unique, fully-integrated biopharmaceutical and diagnostics company founded in 2007. Its core strategy combines the steady, high-volume revenue of its BioReference Laboratories diagnostics business with targeted therapeutic R&D in multispecific antibodies and long-acting delivery technologies. Key achievements include the global commercialization of NGENLA™ (somatrogon) with Pfizer and the marketing of RAYALDEE® for secondary hyperparathyroidism, while its research subsidiary, ModeX Therapeutics, advances a novel pipeline with partners like Merck and Regeneron. This hybrid model aims to de-risk drug development while pursuing transformative medicines for complex diseases.
View full company profileTherapeutic Areas
Other Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| Palopegteriparatide (TransCon PTH) | VISEN Pharmaceuticals | Phase 3 |
| EB-612 | Extend Biosciences | Phase 2 |
| Hypoparathyroidism Program | Confo Therapeutics | Discovery |
| Canvuparatide (MBX 2109) | MBX Biosciences | Phase 2 |
| SEP-479 (PTH1R) | Septerna | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |
| Oral Long-Acting PTH | Entera Bio | Discovery/Preclinical |